ArticleBMC neurology2025
Evaluating the potential of sNfL as a biomarker in MS management in the UK: insights from SUNLIT survey.
Article in BMC neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCurrent evidence supports the use of NfL as a biomarker for neuroaxonal damage in multiple sclerosis (MS), but translation from clinical trials to clinical practice is needed to guide optimal patient management.
methodsThe SUNLIT survey, led by the Novartis medical science liaisons in collaboration with leading MS experts, aimed to assess the utility of sNfL as a biomarker for MS in routine clinical practice within UK. The survey included key questions to assess the clinician’s opinion and level of understanding of sNfL, experience with sNfL measurement, potential drivers and barriers to sNfL testing, identification of potential patient targets and potential impact of sNfL testing on the management of MS, and the role of guidelines for on the adoption of sNfL into clinical practice for MS management across the UK.
resultsA total of 86 clinicians (neurologists specialising in MS, n = 45; MS nurse practitioners, n = 41) from the UK participated in the survey. All HCPs responded to all the survey questions. The findings from the neurologist interviews were positive, supporting the use of sNfL if available (98%). Neurologists perceived that sNfL testing could be used at multiple points in the MS patient management pathway, commonly at treatment switch or initiation, and that it could potentially reduce frequency of MRI scans. The majority of clinicians demonstrated a moderate level of understanding regarding sNfL data in MS; with most clinicians perceiving a need for additional education, and low awareness of existing guidelines on sNfL testing in MS management. Access to sNfL testing and potential confounders like age and BMI were identified as potential barriers to its implementation.
conclusionsThe SUNLIT survey provides important insights into the opinion of HCPs on the potential role of sNfL as a biomarker for MS in the UK. The high level of interest in sNfL testing, coupled with the identified barriers and need for additional education, highlights the need for concerted efforts to support the adoption of sNfL in clinical practice. By addressing these challenges, sNfL has the potential to significantly enhance the management of MS, providing clinicians with a valuable tool for monitoring disease activity and informing treatment decisions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.